---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-226929"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:33:45.187587+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres stockholders approve sale of VOWST business to Nestlé; close expected Sept 30

## Summary
- Stockholders voted 77.1M for, 7.1M against, and 0.2M abstain to approve the sale of VOWST business to Société des Produits Nestlé S.A.
- Non-binding advisory compensation proposal for named executives also passed (63.1M for, 20.9M against, 0.4M abstain).
- Transaction expected to close on September 30, 2024, subject to customary closing conditions.
- VOWST is a microbiome therapeutic; the sale was originally announced under an asset purchase agreement dated August 5, 2024.

## SEC filing metadata
- accession: 0001193125-24-226929
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524226929/0001193125-24-226929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524226929/d713439d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-226929
- JSON: https://secwatch.observer/filing/0001193125-24-226929.json
- Plain text: https://secwatch.observer/filing/0001193125-24-226929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.